C17orf87 Polyclonal Antibody, APC Conjugated
Applications
Reactivity
| Overview | |
| Catalog # | bs-13685R-APC |
| Product Name | C17orf87 Polyclonal Antibody, APC Conjugated |
| Applications |
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human |
| Specifications | |
| Conjugation | APC |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human C17orf87 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Subcellular location | Cell membrane |
| Synonyms | C17orf87; CQ087_HUMAN; DTFT5783; SCIMP; SLP adaptor and CSK interacting membrane protein; SLP65/SLP76; Transmembrane protein C17orf87; UNQ5783; UNQ5783/PRO16090. |
| Background | C17orf87 (chromosome 17 open reading frame 87) is a 145 amino acid protein that is encoded by a gene mapping to human chromosome 17. Chromosome 17 makes up over 2.5% of the human genome with about 81 million bases encoding over 1,200 genes. Two key tumor suppressor genes are associated with chromosome 17, namely, p53 and BRCA1. Tumor suppressor p53 is necessary for maintenance of cellular genetic integrity by moderating cell fate through DNA repair versus cell death. Malfunction or loss of p53 expression is associated with malignant cell growth and Li-Fraumeni syndrome. Like p53, BRCA1 is directly involved in DNA repair, specifically it is recognized as a genetic determinant of early onset breast cancer and predisposition to cancers of the ovary, colon, prostate gland and fallopian tubes. Chromosome 17 is also linked to neurofibromatosis, a condition characterized by neural and epidermal lesions, and dysregulated Schwann cell growth. Alexander disease, Birt-Hogg-Dube syndrome and Canavan disease are also associated with chromosome 17. |
| Application Dilution | |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is C17orf87 Polyclonal Antibody, APC Conjugated (bs-13685R-APC) validated for, and at what dilution?
bs-13685R-APC is validated for IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does C17orf87 Polyclonal Antibody, APC Conjugated (bs-13685R-APC) react with?
Tested reactivity: Human.
How should bs-13685R-APC be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise C17orf87 Polyclonal Antibody, APC Conjugated (bs-13685R-APC)?
KLH conjugated synthetic peptide derived from human C17orf87
What are the excitation and emission wavelengths of the APC conjugate (bs-13685R-APC)?
APC on bs-13685R-APC: excitation / emission 650nm/660nm.